CeriBell (NASDAQ:CBLL) Price Target Raised to $33.00

by · The Markets Daily

CeriBell (NASDAQ:CBLL – Free Report) had its target price raised by Canaccord Genuity Group from $31.00 to $33.00 in a research note published on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other research analysts have also recently issued research reports about the stock. Bank of America started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 target price on the stock. JPMorgan Chase & Co. began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price objective for the company. William Blair started coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “outperform” rating on the stock. TD Cowen began coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $31.00 price target on the stock. Finally, Canaccord Genuity Group initiated coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $32.60.

Read Our Latest Analysis on CBLL

CeriBell Stock Performance

NASDAQ:CBLL opened at $29.61 on Monday. CeriBell has a 1-year low of $23.00 and a 1-year high of $32.53.

CeriBell (NASDAQ:CBLL – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to the consensus estimate of $17.06 million. Analysts predict that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

(Get Free Report)

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

Further Reading